Cure My Disease

Don't miss your cure!

 Log in / Sign up

How big is the threat of Drug-Resistant infections in hospital wards?

NCT ID NCT07797569

Knowledge-focused Sponsor: Hospital Italiano de Buenos Aires Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This study measures how common infections caused by multidrug-resistant organisms are among adults hospitalized in general medical and surgical wards in Argentina, and whether these infections are linked to death in the hospital. On a single day in August 2026, doctors at participating hospitals will record information about every adult patient who has been in a general ward for at least 24 hours, including any active infections and the germs causing them. No tests or treatments are given; the team only reviews existing hospital records. Each patient is then followed for up to 60 days to see if they are discharged alive or die in the hospital.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal the true burden of drug-resistant infections in general hospital wards, guiding better infection control and antibiotic policies in Argentina and beyond.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The single-day snapshot may not reflect long-term trends, and results from Argentina may not apply to other countries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,000 people

The number who actually took part.

Started

Aug 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (≥18 years) hospitalized in general medical/surgical wards of public, social-security, and private hospitals across Argentina that agreed to participate in the study, present in the ward for at least 24 hours before the designated single-day prevalence assessment (August 4-6, 2026). The accessible population includes all such patients at participating sites; no additional selection or exclusion based on diagnosis, infection status, or clinical severity was applied - the cohort captures the full spectrum of general ward patients, whether or not they have an active infection.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Hospitalized in a general adult medical or surgical ward (Internación General de Adultos, IGA) at a participating institution * Hospitalized in the ward for at least 24 hours prior to 8:00 AM local time on the site's designated study day (within the window of August 4-6, 2026) Exclusion Criteria: * Hospitalized in an area other than a general adult medical/surgical ward on the study day (e.g., intensive care unit, neonatal unit, pediatric ward) * Hospitalized in the ward for less than 24 hours prior to 8:00 AM local time on the study day

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antimicrobial resistance (AMR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nosocomial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antimicrobial resistance (AMR) Healthcare-associated infections (HAIS) Multidrug-resistant organism infection

Contacts and locations

Locations

  • Hospital Italiano de Buenos Aires

    CABA, Buenos Aires F.D., 1199, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.